2021-01-CAP: The PROGRESS Trial – Continued Access (A Prospective, Randomized, Controlled Trial to Assess the Management of Moderate Aortic Stenosis by Clinical Surveillance or Transcatheter Aortic Valve Replacement)
Principal Investigator:: Benjamin Galper, MD
Contact: Kara Wright, RN, BSN, Clinical Research Nurse, 240-632-4285
A Randomized, Comparative Effectiveness Study of Staged Complete Revascularization with Percutaneous Coronary Intervention to Treat Coronary Artery Disease vs Medical Management Alone in Patients with Symptomatic Aortic Valve Stenosis undergoing Elective Transfemoral Transcatheter Aortic Valve Replacement: The COMPLETE TAVR Study
Principal Investigator: Benjamin Galper, MD
Contact: Kara Wright, RN, BSN, Clinical Research Nurse, 240-632-4285
DS102A-10-RD2: An Open-Label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients with Sickle Cell Disease
Principal Investigator: Bogdan Dumitriu, MD
Contact: Grace Adumanisa, Clinical Research Coordinator, 240-632-4285
VX21-147-301: A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 12 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Principal Investigator: PI: Tulsi Mehta, MD
Contact: Kazzmine Moses, DC, Clinical Research Coordinator, 240-632-4285
No Clinical Trials
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Principal Investigator: Dr. James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Clinical Trials Research Nurse Manager, 240-632-4285
A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Principal Investigator: Dr. James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Clinical Trials Research Nurse Manager, 240-632-4285
NRG-GI004: Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Principal Investigator: Dr. James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Clinical Trials Research Nurse Manager, 240-632-4285
Lung-MAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Principal Investigator: Dr. James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Clinical Trials Research Nurse Manager, 240-632-4285
S1900G: A Randomized Phase II Study of Capmatinib Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Principal Investigator: Dr. James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Clinical Trials Research Nurse Manager, 240-632-4285
NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)
Principal Investigator: Dr. James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Clinical Trials Research Nurse Manager, 240-632-4285
NRG-CC005: FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)
Principal Investigator: Dr. James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Clinical Trials Research Nurse Manager, 240-632-4285
S1900K: A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
Principal Investigator: James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Clinical Trials Research Nurse Manager, 240-632-4282
A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Principal Investigator: James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Clinical Trials Research Nurse Manager, 240-632-4285
KMT013: A Multisite Prospective Study to Assess the Clinical Effectiveness of a Novel Medical Technology as an Extra Reader for Breast Cancer Screening
Principal Investigator: Wilbur Chang, MD
Contact: Leslie Greenberg, MSN, MBA, RN, OCN®, Director of Clinical Trials, 301-373-0969
NRG-BR009: Ph. III Adjuvant Trial Evaluating the Addition of Adj. Chemotherapy to Ovarian Function Suppression + Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)
Principal Investigator: James Liu, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Clinical Trials Research Nurse Manager, 240-632-4285
S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Principal Investigator: Leon Hwang, MD
Contact: Charmaine McKie, PhD, MPH, RN, OCN®, CNE, Clinical Trials Research Nurse Manager, 240-632-4285